Otros idiomas BriaCell Therapeutics Corp.

Acciones

BCT

CA1079301091

Mercado cerrado - Toronto S.E. Otros sitios de cotización 21:58:02 28/06/2024			Varia. Cinco días.	Varia. 1 de enero.
1,525 ^CAD	+8,16 %		-5,86 %	-80,45 %

14/06	BriaCell Therapeutics Corp. informa de los resultados del tercer trimestre y de los nueve meses finalizados el 30 de abril de 2024	CI
03/06	Briacell Therapeutics Corp. presenta datos de eficacia clínica en ASCO 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Form 8 K	14/06
BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	14/06
BriaCell Presents Clinical Efficacy Data at ASCO 2024	03/06
Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024	03/06
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer	31/05
BriaCell Begins Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer	30/05
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer	30/05
BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer	30/05
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	28/05
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	28/05
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	28/05
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	28/05
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024	24/05
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing	20/05
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering	17/05
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	15/05
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering	15/05
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	24/04
BriaCell Announces Oral and Poster Presentations at ASCO 2024	24/04
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer	10/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas BriaCell Therapeutics Corp.

Acciones

BCT

CA1079301091

Otros idiomas

Filtros